key: cord-0946898-5u8j31ez authors: El‐Battrawy, Ibrahim; Longo, Filomena; Núñez Gil, Iván J.; Abumayyaleh, Mohammad; Gianesin, Barbara; Estrada, Vicente; Aparisi, Álvaro; Arroyo‐Espliguero, Ramón; Balocco, Manuela; Barella, Susanna; Beccaria, Andrea; Bonetti, Federico; Casale, Maddalena; De michele, Elisa; Denotti, Anna Rita; Fidone, Carmelo; Fortini, Monica; Gamberini, Maria Rita; Graziadei, Giovanna; Lisi, Roberto; Massa, Antonella; Marcon, Alessia; Rubinski, Bryan; Miano, Maurizio; Motta, Irene; Pinto, Valeria Maria; Piperno, Alberto; Mariani, Raffaella; Putti, Maria Caterina; Quota, Alessandra; Ribersani, Michela; Marziali, Marco; Roberti, Domenico; Rosso, Rosamaria; Tartaglione, Immacolata; Vitucci, Angelantonio; Voi, Vincenzo; Zecca, Marco; Romero, Rodolfo; Marouneld, Charbel; Fernández‐Rozas, Inmaculada; Espejo, Carolina; Marhaeni, Wulandewi; Garcia Aguado, Marcos; Cappellini, Maria Domenica; Perrotta, Silverio; De Franceschi, Lucia; Piga, Antonio; Forni, Gian Luca; Akin, Ibrahim title: Thalassaemia is paradoxically associated with a reduced risk of in‐hospital complications and mortality in COVID‐19: Data from an international registry date: 2022-03-30 journal: J Cell Mol Med DOI: 10.1111/jcmm.17026 sha: 64930720eb210ea97f7f7c3d655a8b064e12299e doc_id: 946898 cord_uid: 5u8j31ez Although numerous patient‐specific co‐factors have been shown to be associated with worse outcomes in COVID‐19, the prognostic value of thalassaemic syndromes in COVID‐19 patients remains poorly understood. We studied the outcomes of 137 COVID‐19 patients with a history of transfusion‐dependent thalassaemia (TDT) and transfusion independent thalassaemia (TIT) extracted from a large international cohort and compared them with the outcomes from a matched cohort of COVID‐19 patients with no history of thalassaemia. The mean age of thalassaemia patients included in our study was 41 ± 16 years (48.9% male). Almost 81% of these patients suffered from TDT requiring blood transfusions on a regular basis. 38.7% of patients were blood group O. Cardiac iron overload was documented in 6.8% of study patients, whereas liver iron overload was documented in 35% of study patients. 40% of thalassaemia patients had a history of splenectomy. 27.7% of study patients required hospitalization due to COVID‐19 infection. Amongst the hospitalized patients, one patient died (0.7%) and one patient required intubation. Continuous positive airway pressure (CPAP) was required in almost 5% of study patients. After adjustment for age‐, sex‐ and other known risk factors (cardiac disease, kidney disease and pulmonary disease), the rate of in‐hospital complications (supplemental oxygen use, admission to an intensive care unit for CPAP therapy or intubation) and all‐cause mortality was significantly lower in the thalassaemia group compared to the matched cohort with no history of thalassaemia. Amongst thalassaemia patients in general, the TIT group exhibited a higher rate of hospitalization compared to the TDT group (p = 0.001). In addition, the rate of complications such as acute kidney injury and need for supplemental oxygen was significantly higher in the TIT group compared to the TDT group. In the multivariable logistic regression analysis, age and history of heart or kidney disease were all found to be independent risk factors for increased in‐hospital, all‐cause mortality, whereas the presence of thalassaemia (either TDT or TIT) was found to be independently associated with reduced all‐cause mortality. The presence of thalassaemia in COVID‐19 patients was independently associated with lower in‐hospital, all‐cause mortality and few in‐hospital complications in our study. The pathophysiology of this is unclear and needs to be studied in vitro and in animal models. patients with no history of thalassaemia. The mean age of thalassaemia patients included in our study was 41 ± 16 years (48.9% male). Almost 81% of these patients suffered from TDT requiring blood transfusions on a regular basis. 38.7% of patients were blood group O. Cardiac iron overload was documented in 6.8% of study patients, whereas liver iron overload was documented in 35% of study patients. 40% of thalassaemia patients had a history of splenectomy. 27.7% of study patients required hospitalization due to COVID-19 infection. Amongst the hospitalized patients, one patient died (0.7%) and one patient required intubation. Continuous positive airway pressure (CPAP) was required in almost 5% of study patients. After adjustment for age-, sexand other known risk factors (cardiac disease, kidney disease and pulmonary disease), the rate of in-hospital complications (supplemental oxygen use, admission to an intensive care unit for CPAP therapy or intubation) and all-cause mortality was significantly lower in the thalassaemia group compared to the matched cohort with no history of thalassaemia. Amongst thalassaemia patients in general, the TIT group exhibited a higher rate of hospitalization compared to the TDT group (p = 0.001). In addition, the rate of complications such as acute kidney injury and need for supplemental oxygen was significantly higher in the TIT group compared to the TDT group. In the multivariable logistic regression analysis, age and history of heart or kidney disease were all found to be independent risk factors for increased in-hospital, all-cause mortality, whereas the presence of thalassaemia (either TDT or TIT) was found to be independently associated with reduced all-cause mortality. The presence of thalassaemia in COVID-19 patients was independently associated with lower in-hospital, all-cause Since publication of the first reports on COVID-19, the highest incidence and mortality rates have been reported in the USA, Italy, Spain, China and France, 1 with nearly 2.2 million deaths and more than 103,000,000 infections having been reported worldwide to date. [2] [3] [4] [5] Although patients may present with symptoms such as fever, myalgia, fatigue, dry cough and/or diarrhea, 6 asymptomatic patients are not rare. Different models have been developed to date to analyse the severity of COVID-19, with numerous co-factors having been reported as predictors of worse outcomes such as arterial hypertension, diabetes mellitus, heart disease, acute and chronic kidney disease, chronic pulmonary disease, advanced age, immunosuppression and inherited haemoglobin disorders. [7] [8] [9] [10] [11] Few data have been published to date on COVID-19 and thalassaemia syndrome and the existing data are still controversial due to the small number of patients included. 8, [12] [13] [14] Thalassaemia patients may be at high risk for infectious complications leading to increased mortality and morbidity. This may be due to splenectomy, adrenal insufficiency, stem cell transplantation and/or stress erythropoiesis. 15 Despite advances in the understanding of the pathophysiology of thalassaemia over the last decade, management of this disease has remained largely unchanged over the years. 16 In this present study, we described the clinical characteristics and outcomes of a cohort of COVID-19 patients suffering from concomitant thalassaemia using data from a large, international observational study and compared them to a matched cohort with no history of thalassaemia. The data set included different clinical forms of β-thalassaemia, including the co-inheritance of β-thalassaemia with haemoglobin E resulting in haemoglobin E/β-thalassaemia. Patients were managed according to the current recommendations for the treatment of thalassaemia. 14 The primary outcome was in-hospital, all-cause mortality. In addition, in-hospital complications including admission to an intensive care unit (ICU), as well as the type of respiratory support needed (nasal cannula, non-invasive mechanical ventilation, invasive mechanical ventilation or invasive mechanical support), were also evaluated in the outcome analysis. Epidemiological, clinical and outcome data were collected from the electronic medical records. The confidentiality of patient data was protected by storing them in an anonymous manner on a locked, mortality and few in-hospital complications in our study. The pathophysiology of this is unclear and needs to be studied in vitro and in animal models. COVID-19, mortality, SARS-CoV-2, thalassaemia | 2523 EL-BATTRAWY ET AL. Continuous variables with a normal distribution are shown as mean ± standard deviation, continuous variables with a non-normal distribution are shown as a median (interquartile range) and categorical variable are shown as a frequency (% Table 1 . Table S1 presents the cohort of 134 patients separated into a TIT and a TDT group. The information regarding a history of transfusion was missing in three patients. Patients in the TIT group were in general older than in the TDT group (54.7 ± 18.6 years versus 38 ± 14, p < 0.001) and hospitalized more often (p = 0.001). Symptoms such as dyspnoea, fatigue, fever and cough were significantly more prevalent in the TIT group compared to TDT group. In-hospital complications were similar between groups except with regard to the need for supplemental oxygen and acute kidney injury, both of which were more common in the TIT group. 27.7% of the thalassaemia patients were hospitalized due to COVID-19 and 18% of patients required admission to an intensive care unit (ICU). The main presenting symptoms were as follows: In the propensity score matching, 127 COVID-19 patients with concomitant thalassaemia were matched to 127 patients suffering from COVID-19 with no history of thalassaemia. Patients with no history of thalassaemia exhibited significantly higher rates of hospitalization than those with a history of thalassaemia as seen in Table 3 We matched the thalassaemia patients with COVID-19 patients in absence of thalassaemia to assess for predictors of in-hospital, all-cause mortality. In the univariate analysis, male gender, age, thalassaemia, pulmonary disease, cardiac disease, kidney disease and diabetes were all found to predict all-cause mortality. Using a multivariable logistic regression analysis ( This present study examined patient characteristics, in-hospital complications and outcomes of COVID-19 patients with and without a history of thalassaemia. The main findings of our study were as follows: (1) Thalassaemia is an independent predictor of reduced in-hospital, all-cause mortality compared to patients with no history of thalassaemia. To date, various co-factors have been identified as being associated with increased mortality in COVID-19 patients, amongst these cancer and hemoglobinopathies. 6 With regard to thalassaemia, the data from a small number of case series and case reports have been In this Iranian cohort, the splenectomy rate was at least 80%. 11 On the other hand, preliminary data from 11 thalassaemia patients from different Italian centres hinted at milder outcomes in COVID-19 disease with all patients recovering completely. 13 A different study from centres in 10 different countries summarized data from at least 10 beta-thalassaemia patients. In this study, one patient (10%) died despite respiratory support and intensive care unit stay. 8 Only 40% of these patients had a history of splenectomy. The mortality rate of 0.7% in our study seems to be very low in comparison, but included a far greater sample size. Approximately 40% of patients in our study had a history of splenectomy. This is comparable to the recently published study, however, with a lower mortality rate. 13 We compared data from thalassaemia patients with COVID-19 to a matched cohort of COVID-19 patients with no history of thalassaemia and, seemingly paradoxically, found a significantly lower inhospital, all-cause mortality rate in the thalassaemia cohort and a lower rate of in-hospital complications. Although the rate of liver disease was higher in thalassaemia patients compared to the age-, gender-and cardiovascular disease-matched group of COVID-19 patients, the mortality rate was much lower. Of note, recently published data described a worse prognosis in patients with liver disease, and reported a mortality rate of approximately 15%. 17 Despite the higher prevalence of liver disease in our thalassaemia cohort compared to patients with no history of thalassaemia, the outcomes were still better in patients with thalassaemia. In a nationwide Iranian cohort, 36.4% had a heart and liver iron overload. Our present data showed an overload of iron in the heart and liver in 6.8% and 35%. These data appear to confirm a lower risk of mortality in thalassaemia patients. In our present study cohort, 99% of patients recovered from COVID-19. Whereas the need for intubation was documented in only one patient, non-invasive respiratory support was required in seven patients in our study. Compared to the matched cohort, however, these rates were still significantly lower than in the non-thalassaemia group. The mild courses of COVID-19 in the thalassaemia cohort may be related to different factors. Recently published data showed that ORF8 and surface glycoproteins of COVID-19 could form a complex together with porphyrin. In addition, orflab, ORF10 and ORF3a proteins could attack the porphyrin, which is formed in the mitochondria on the 1beta chain of haemoglobin. 18, 19 This may lead to dissociation of iron from porphyrin. Genetic mutations may result in the absence of beta chain synthesis while retaining normal alpha chain synthesis. This could overall lead to less haemoglobin A being produced. Since the beta chain s a potential target for COVID-19 infection is either absent or expressed at a much lower rate in the blood of thalassaemia patients, this may lead to decreased susceptibility to COVID-19 infection in thalassaemia patients. 17 Of note, a history of regular blood transfusions was documented more than 80% of our thalassaemia patients. But nevertheless, in vitro and animal studies are required to confirm this hypothesis. It might be speculated that in transfusiondependent patients when pretransfusion haemoglobin goal is 9-10 g/ dl, their bone marrow is supposed to be suppressed by transfusions therefore the majority of haemoglobin A is from normal transfused red cells and less produced by patients own abnormal red blood cells. It could be that protecting red cells from COVID-19 will be irrelevant in TDT patients but could apply to TIT patients. Compared to the matched cohort, COVID-19 symptoms were significantly lower amongst thalassaemia patients. In the Iranian thalassaemia registry, the prevalence of COVID-19 was 0.14% in the thalassaemia patients. On this point, we cannot provide any data regarding the prevalence of COVID-19 in thalassaemia patients since we included all patients with COVID-19 and did not analyse the number of thalassaemia patients in each and every centre. Analysis of the data of this large international cohort revealed a lower all-cause mortality rate in thalassaemia patients compared to a matched cohort with no history of thalassaemia. In-hospital complications relating to COVID-19 infection were also significantly lower in thalassaemia patients, although the hospitalization rate was 27.7%, which was significantly lower than in the matched cohort. Data for this study were collected from several centres and bias regarding the heterogeneous diagnostic and treatment strategies between them cannot be excluded. In addition, there are differences in the capacity and other medical resources available in these centres. Although the data summarized in this study came from an international registry, the majority of patients included were from European countries (Italy and Spain) and outcomes may differ due to ethnic factors and standard of care in other parts of the world. equal); Formal analysis (equal) Supervision (equal); Validation (equal) Filomena Longo: Data curation (equal); Formal analysis (equal) Data curation (equal); Formal analysis (equal) Barbara Gianesin: Data curation (equal); Formal analysis (equal). Vicente Estrada: Data curation (equal) Andrea Beccaria: Data curation (equal). Federico Bonetti: Conceptualization (equal); Data curation (equal). Maddalena Casale: Data curation (equal) Carmelo Fidone: Data curation (equal). Monica Fortini: Formal analysis (equal) Maria Rita Gamberini: Data curation (equal) Antonella Massa: Data curation (equal) Maurizio Miano: Formal analysis (equal) Irene Motta: Software (equal) Valeria Pinto: Validation (equal) Alberto Piperno: Supervision (equal) Raffella Mariani: Methodology (equal) Maria Caterina Putti: Visualization (equal). Alessandra Quota: Software (equal) Marco Marziali: Data curation (equal). Domenico Roberti: Formal analysis (equal) Angelantonio Vitucci: Data curation (equal). Vincenzo Voi: Data curation (equal). Marco Zecca: Data curation Rodolfo Romero: Data curation (equal) Charbel Marouneld: Methodology (equal) Data curation (equal). Carolina Espejo: Investigation (equal) Maria Domenica Cappelini: Software (equal) Antonio Piga: Formal analysis (equal) Visualization (equal); Writing-original draft (equal) Writing-review & editing (equal) Raw data are available on request by the correspoinding author O RCI D Ibrahim El Maddalena Casale Immacolata Tartaglione Clinical features of patients infected with 2019 novel coronavirus in Wuhan Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China The landscape of COVID-19 in cancer patients: prevalence, impacts, and recommendations Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Preliminary data on COVID-19 in patients with hemoglobinopathies: a multicentre ICET-a study Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health outcome predictive evaluation for COVID 19) registry Prevalence and mortality in beta-thalassaemias due to outbreak of novel coronavirus disease (COVID-19): the nationwide Iranian experience Impact of COVID-19 Infection on 24 patients with sickle cell disease SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience The alpha-thalassemias Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study COVID-19: beta-thalassemia subjects immunised? Med Hypotheses COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit heme metabolism Relationship between the ABO blood group and the COVID-19 susceptibility COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany) We would like to thank Cardiovascular Excellence SL for their essential support in the database and the HOPE webpage as well as ALT (Associazione per la Lotta alla Talassemia R. Vullo-Ferrara, Italy). The authors declare no conflicts of interest. Ibrahim El-Battrawy: Conceptualization (equal); Data curation Additional supporting information may be found in the online version of the article at the publisher's website.